| $385M | ||
| $337M | ||
| $100M | ||
| $87M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
Over the last 12 months, insiders at Contineum Therapeutics, Inc. Class A Common Stock have bought $0 and sold $0 worth of Contineum Therapeutics, Inc. Class A Common Stock stock.
On average, over the past 5 years, insiders at Contineum Therapeutics, Inc. Class A Common Stock have bought $0 and sold $117,598 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2024-11-25 | Sale | Lorrain Daniel S. | Chief Scientific Officer | 1,010 0.0042% | $16.02 | $16,177 | -49.58% | |
| 2024-11-18 | Sale | Lorrain Daniel S. | Chief Scientific Officer | 6,190 0.0264% | $16.38 | $101,421 | -50.88% |
| Increased Positions | 34 | +37.36% | 5M | +36.29% |
| Decreased Positions | 40 | -43.96% | 2M | -11.57% |
| New Positions | 16 | New | 3M | New |
| Sold Out Positions | 22 | Sold Out | 914,871 | Sold Out |
| Total Postitions | 85 | -6.59% | 18M | +24.72% |
| Ra Capital Management, L.P. | $23,491.00 | 9.23% | 2.12M | +2M | New | 2025-09-30 |
| Johnson & Johnson | $21,909.00 | 8.61% | 1.98M | 0 | 0% | 2025-09-30 |
| Suvretta Capital Management, Llc | $19,040.00 | 7.48% | 1.72M | 0 | 0% | 2025-09-30 |
| Franklin Resources Inc | $18,327.00 | 7.2% | 1.66M | -43,277 | -2.55% | 2025-09-30 |
| Vanguard Group Inc | $10,674.00 | 4.19% | 964,232 | +220,231 | +29.6% | 2025-09-30 |
| Balyasny Asset Management L.P. | $10,531.00 | 4.14% | 951,320 | +951,320 | New | 2025-09-30 |
| Fmr Llc | $9,021.00 | 3.54% | 814,871 | -28,279 | -3.35% | 2025-09-30 |
| Sectoral Asset Management Inc | $8,865.00 | 3.48% | 800,787 | 0 | 0% | 2025-09-30 |
| Perceptive Advisors Llc | $7,911.00 | 3.11% | 714,592 | +15,106 | +2.16% | 2025-09-30 |
| Hhlr Advisors, Ltd. | $7,410.00 | 2.91% | 669,337 | 0 | 0% | 2025-09-30 |